Loading...
•
Mar 31
SIGA Technologies Q1 2025 Earnings Report
SIGA Technologies reported its financial results for the first quarter ended March 31, 2025, showing a decrease in product sales and a net loss compared to the previous year.
Key Takeaways
SIGA Technologies reported total revenues of $7.0 million for the first quarter of 2025, a significant decrease from $25.4 million in the same period last year. The company experienced a net loss of $0.4 million, or $0.01 per diluted share, compared to a net income of $10.3 million, or $0.14 per diluted share, in Q1 2024. Despite the decline in sales, SIGA highlighted steady progress on key initiatives and anticipated substantial sales in the coming months from outstanding orders.
Total revenues for Q1 2025 were $7.0 million, down from $25.4 million in Q1 2024.
The company reported a net loss of $0.4 million in Q1 2025, compared to a net income of $10.3 million in Q1 2024.
Diluted loss per share was $0.01 in Q1 2025, a decrease from diluted income per share of $0.14 in Q1 2024.
Operating loss for Q1 2025 was $2.3 million, a significant shift from an operating income of $11.3 million in Q1 2024.
SIGA Technologies
SIGA Technologies
SIGA Technologies Revenue by Segment
Revenue by Segment
Product sales & supportive services Revenue
CapyFin.comResearch and development Revenue
CapyFin.com Forward Guidance
SIGA expects to deliver $70 million of outstanding orders from December 31, 2024, by the end of the third quarter of 2025, with the remainder expected in 2026. The company views these anticipated sales as a strong base for future growth.
Positive Outlook
- Expects to deliver $70 million of outstanding orders by the end of Q3 2025.
- Anticipates substantial international sales over the next series of months.
- Views anticipated sales as a strong base for future growth.
- Received regulatory approval for TEPOXX in Japan for orthopoxviruses.
- Modified 19C contract with U.S. Government to add $14 million for manufacturing support.
Challenges Ahead
- Risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms.
- Risk that the BARDA Contract or U.S. Department of Defense contracts are modified or canceled.
- Risk that the nascent international biodefense market does not develop sufficiently.
- Risk that potential products cannot be shown to be efficacious or safe in subsequent trials.
- Risk that target timing for product deliveries and revenue recognition are delayed or adversely impacted by supply chain issues.
Revenue & Expenses
Visualization of income flow from segment revenue to net income